Compared with differentiating between CRA and CRC cohorts, the d-signature had higher diagnostic efficiency to differentiate between healthy and CRC cohorts, including early-stage (stage I–II) CRC and CEA-negative CRC. Here, CEACAM5 is linked to colorectal carcinoma.